Phase II trial of a novel immunotherapy combination of pembrolizumab and HER2 bi-armed activated T cells (BATs) in metastatic castrate resistant prostate cancer.

docetaxel - Generic mfg.

Keytruda (pembrolizumab) - Merck (MSD)

HER2Bi-armed ATC - TransTarget

https://meetinglibrary.asco.org/record/183608

Meera Patel; Lawrence G. Lum; Abhinav Deol; Archana Thakur; Elisabeth I. Heath; Wei Chen; Kimberlee Dobson; Joseph A. Fontana; Ulka N. Vaishampayan

Dec 22, 2019